US equities
|
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
InMed Pharmaceuticals Inc. - Common Shares
(NQ:
INM
)
1.599
+0.009 (+0.58%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about InMed Pharmaceuticals Inc. - Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT
↗
January 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a...
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 20, 2022
Via
Investor Brand Network
Topics
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 19, 2022
Via
Investor Brand Network
Topics
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 19, 2022
Via
CannabisNewsWire
Topics
Supply Chain
InMed Pharmaceuticals' Issues Annual Shareholder Letter
↗
January 05, 2022
InMed Pharmaceuticals (NASDAQ:
Via
Benzinga
4 Penny Stocks Insiders Are Buying
↗
January 07, 2022
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...
Via
Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Issues Annual Shareholder Letter
January 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
January 05, 2022
Via
Investor Brand Network
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event
↗
December 30, 2021
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and...
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
December 30, 2021
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
December 30, 2021
Via
Investor Brand Network
InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment
↗
December 20, 2021
InMed Pharmaceuticals (NASDAQ:
Via
Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment
December 20, 2021
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment
December 20, 2021
Via
Investor Brand Network
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
↗
December 10, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following...
Via
Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
December 10, 2021
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
December 09, 2021
Via
Investor Brand Network
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
↗
December 01, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio...
Via
Benzinga
Topics
Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
November 30, 2021
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
November 30, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
↗
November 29, 2021
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
↗
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
November 29, 2021
Via
Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
November 29, 2021
Via
CannabisNewsWire
InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference
↗
November 23, 2021
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis...
Via
Benzinga
Topics
Cannabis
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
November 23, 2021
Via
Investor Brand Network
Topics
Cannabis
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021
↗
November 18, 2021
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban...
Via
Benzinga
Topics
Cannabis
54 Biggest Movers From Yesterday
↗
November 19, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company...
Via
Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
↗
November 18, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
November 18, 2021
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
